FDA APPROVES TRASTUZUMAB DERUXTECAN FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR BREAST CANCER

Share

Share on facebook
Share on linkedin
Share on twitter
Share on email

On May 4, 2022, the Food and Drug Administration (FDA) approved Enhertu (trastuzumab deruxtecan) treatment from Daiichi Sankyo Company and AstraZeneca, for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received two or more treatment regimens based on anti-HER2 therapies. The treatment is approved in the metastatic setting or in the neoadjuvant or adjuvant setting, and for those patients who have developed disease recurrence during or within 6 months after completion of treatment.

Download here